Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Rating) have been given a consensus rating of “Buy” by the nine research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $27.29.
A number of equities research analysts recently weighed in on the company. Brookline Capital Acquisition assumed coverage on Caribou Biosciences in a research note on Monday, February 14th. They issued a “buy” rating and a $19.00 price target on the stock. Royal Bank of Canada assumed coverage on Caribou Biosciences in a research note on Thursday, February 17th. They issued an “outperform” rating and a $22.00 price target on the stock. Brookline Capital Management restated a “buy” rating on shares of Caribou Biosciences in a research note on Monday, February 14th. SVB Leerink decreased their price objective on Caribou Biosciences from $32.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, March 22nd. Finally, Zacks Investment Research raised Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 12th.
Shares of Caribou Biosciences stock opened at $7.40 on Friday. Caribou Biosciences has a 12-month low of $7.04 and a 12-month high of $32.65. The business’s 50 day moving average is $8.85 and its 200-day moving average is $13.52.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $206,000. Victory Capital Management Inc. acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $2,027,000. New York State Common Retirement Fund acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $414,000. Herold Advisors Inc. acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $60,000. Finally, Deutsche Bank AG acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $279,000. 62.86% of the stock is currently owned by hedge funds and other institutional investors.
About Caribou Biosciences (Get Rating)
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.
- Get a free copy of the StockNews.com research report on Caribou Biosciences (CRBU)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.